This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Wellnara for postmenopausal osteoporosis. The objective of this study is to assess safety and efficacy of using Wellnara in clinical practice. A total 400 patients will be recruited and followed 3 years since starting Wellnara administration.
Study Type
OBSERVATIONAL
Enrollment
411
Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
Unnamed facility
Many Locations, Japan
Incidence of adverse drug reactions and serious adverse events in subject who received Wellnara
Time frame: After Wellnara administration, up to 3 years
Incidence of adverse drug reactions in subpopulation with baseline data (such as demographic data, concomitant disease) and dose of Wellnara
Time frame: At baseline and after Wellnara administration, up to 3 years
Effectiveness evaluation assessment by the three rank scales: improvement, not changed, and worse
Time frame: At baseline and after Wellnara treatment, up to 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.